Search company, investor...
Eckert & Ziegler BEBIG company logo

Eckert & Ziegler BEBIG

Submit Your Analyst Briefing


Acq - P2P | Acquired

About Eckert & Ziegler BEBIG

Eckert & Ziegler BEBIG manufactures and markets radioactive implants and medications used in the treatment of cancer. The company's implants are a localized treatment that kills the cancer without damaging the surrounding tissues.

Headquarters Location

Rue Jules Bordet Zone Industrielle C

Seneffe, 7180,


+32 (0) 64 520 811

Missing: Eckert & Ziegler BEBIG's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eckert & Ziegler BEBIG's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eckert & Ziegler BEBIG

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eckert & Ziegler BEBIG is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Eckert & Ziegler BEBIG Patents

Eckert & Ziegler BEBIG has filed 5 patents.

patents chart

Application Date

Grant Date


Related Topics




Radiation therapy, Medical physics, Radioactivity, Radiobiology, Molecular biology


Application Date


Grant Date



Related Topics

Radiation therapy, Medical physics, Radioactivity, Radiobiology, Molecular biology



Latest Eckert & Ziegler BEBIG News

Radiotherapy Devices Global Market Report 2022

May 24, 2022

Major players in the radiotherapy devices market are Varian Medical Systems, Elekta AB, Accuray Inc, C. R. Bard Inc, IBA Ion Beam Applications SA, Koninklijke Philips N. V, Siemens AG, Eckert & Ziegler Bebig, IsoRay Inc, and GE Healthcare. May 24, 2022 05:28 ET Lyon, FRANCE New York, May 24, 2022 (GLOBE NEWSWIRE) -- announces the release of the report "Radiotherapy Devices Global Market Report 2022" - The global radiotherapy devices market is expected to grow from $4.76 billion in 2021 to $5.21 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The market is expected to grow to $7.47 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The radiotherapy devices market consists of sales of radiotherapy devices and related services by entities (organizations, sole traders, and partnerships) that manufacture radiotherapy devices. Radiotherapy devices are used in cancer treatment by using high doses of radiation to kill cancer cells and shrink tumors. The main product type of radiotherapy devices is external beam radiation therapy devices, linear accelerator devices, and proton therapy devices.A medical linear accelerator (LINAC) is a radiotherapy device that is generally utilized for external beam radiation treatments for patients with cancer. It supplies high-energy x-rays or electrons to the region of the patient’s tumor.The applications are skin cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. These are used in hospitals, ambulatory surgical centers, and oncological treatment centers. North America was the largest region in the radiotherapy devices market in 2021.Asia Pacific was the second largest region in the radiotherapy devices market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Technological advancement is anticipated to drive the demand for the radiotherapy devices market.The advancement in technology is helping to develop low-cost, more effective and efficient, and user-friendly products with precise and improved radiation doses for increased performance in targeting tumors. The advancement from 2D radiotherapy devices to 3D with real-time imaging enabled high conformity of radiation to improve tumor control.For instance, in June 2020, Accuray Incorporated, a US-based radiation oncology company launched CyberKnife S7 System, a radiotherapy device combining advanced precision, real-time artificial intelligence, and speed motion tracking and synchronization treatment delivery for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments. Therefore, the launch of advanced devices is likely to propel the revenues for the radiotherapy devices market shortly. The high cost of radiotherapy is projected to limit the growth of the radiotherapy devices market as it uses complex machines and involves the services of skilled health care providers.The specific expense of radiation treatment relies upon the expense of medicinal services such as place of patient residence, type of radiation treatment, and the number of medicines required. For example, Proton Therapy is a high-cost therapy that is usually performed in metropolitical cities or at major academic centers.The treatment duration is eight weeks, which leads to huge expenditure on treatment and relocation. According to the report of the National Cancer Institutes, approximately $150.8 billion were spent nationally for cancer care in 2018 in America. The high costs of cancer treatment are especially difficult to overcome among the poor or the uninsured or underinsured population. Therefore, the high cost associated with radiotherapy procedures is expected to restrain the growth of the market. Artificial Intelligence (AI) is a leading trend in the radiotherapy devices market and is gaining significant popularity in the market.The incorporation of AI innovation in disease care is expected to improve the exactness and speed of analysis, help clinical dynamics, and lead to better results. For instance, in September 2019, Varian Medical Systems, a US-based manufacturer of radiation oncology medical devices, launched Ethos artificial intelligence radiotherapy device.The traditional treatment arranging process takes days to make an improved radiation treatment conveyance plan; however, the new AI advancements are helping to speed up this procedure. AI is also expected to include deep learning applications in treatment planning, clinical decision support, automated image-guided adaptive radiation therapy, and genomic/radio-biologic data mining, thus supporting the growth of the market. In August 2020, Siemens Healthineers, a Germany-based medical technology company, announced its decision to acquire Varian Medical Systems Inc., for $16.4 billion. The deal is expected to expand Siemens Healthineer’s definitive objective of overarching and comprehensive oncology portfolio, including Varian’s linear accelerators, radiosurgery devices, and proton therapy suites to Siemens’ imaging hardware, laboratory diagnostics, and hospital consulting services. Varian Medical Systems Inc. is a US-based radiation oncology treatments and software company. The countries covered in the radiotherapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

Eckert & Ziegler BEBIG Frequently Asked Questions (FAQ)

  • Where is Eckert & Ziegler BEBIG's headquarters?

    Eckert & Ziegler BEBIG's headquarters is located at Rue Jules Bordet, Seneffe.

  • What is Eckert & Ziegler BEBIG's latest funding round?

    Eckert & Ziegler BEBIG's latest funding round is Acq - P2P.

  • Who are the investors of Eckert & Ziegler BEBIG?

    Investors of Eckert & Ziegler BEBIG include Eckert & Ziegler and Vives.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.